EAGLE GLOBAL SCIENTIFIC

ADVANCED DIAGNOSTICS

LIGHTING THE PATH TO DISCOVERY

Eagle Global Scientific, LLC (EGS) is a certified 8(a) Alaska Native Corporation (ANC) that contracts with federal agencies and military partners through both the direct award and competitive procurement processes. We are a leader in advanced diagnostics and new modalities of disease identification. Our established expertise and partnerships in this area allowed us to immediately respond to the emergence of SARS-CoV-2 and contribute to the development and implementation of accurate diagnostic tests and assays.

As a small business, EGS is singularly qualified to support federal programs in spheres where previously only large companies have been players. Our 8(a) status allows EGS to accept direct awards (sole-source contracts) up to $22 million. Awards to an 8(a) ANC cannot be protested. EGS is fully on-ramped to both the OASIS SB Pool 4 and the SB 8(a) SubPool 4 (NAICS 541715 Scientific Services) contracts.

WORK WITH US

SBA CONTACT
Please contact us directly for more information on our SBA Officer.

EAGLE GLOBAL SCIENTIFIC
SBA Certified 8(a) Contractor
Primary NAICS: 621511
EGS DUNS: 080-02-2933
EGS Cage Code: 7GWG7
OASIS Pool 4
OASIS SB 8(a) SubPool 4

NOVEL DIAGNOSTIC MODALITIES

EGS supported the evaluation of the FilmArray® Instrument for use in the diagnosis of respiratory infections. We facilitated the research collboration, drafted research protocols, and oversaw the expansion to multiple additional testing sites. EGS worked closely with the Center for Global Health (CGH) to implement the Pima™ Analyser, a point-of-care CD4 rapid testing tool. EGS also recruited subject matter experts specializing in coronaviruses; our experts consulted on dynamic coronavirus testing methodologies and refined the diagnostic process in order to develop a kit with improved false positive and false negative rates.

ADVANCED MOLECULAR DETECTION

EGS supports the CDC through a contract for bioinformatics and Advanced Molecular Detection (AMD). Our employees assisted dozens of Principal Investigators with key projects. CDC's AMD program introduces rapid technological innovation to join trusted methods with exciting new horizons in disease detection. By increasing critical next generation sequencing and bioinformatics capacities, the CDC and state health departments will gain ground in the battle to control infectious diseases including the fight against novel infections and global pandemic responses.

PERSONALIZED MEDICINE INNOVATION

EGS scientists provided critical subject matter expertise to the overall design of a panel consisting of seventeen different single nucleotide polymorphisms (SNPs) associated with an increased prevalence of Type 2 Diabetes (T2D). Active-duty service members were tested using an IRB-approved protocol. The results of this diagnostic test drive a "Personalized Medicine" approach for the early detection of T2D. This project demonstrates the promise of using SNPs to determine risk level as a predictive tool to identify individuals that may benefit from lifestyle modification and preventative intervention.

PARTNERS

- Clinical Research Laboratory at Keesler AFB
- Idaho Technologies
- Center for Global Health (CGH), International Laboratory Branch (ILB)
- Office of Advanced Molecular Detection (AMD)
- U.S. Air Force Chief Scientist Office at Lackland AFB
- FilmArray® Instrument
- Pima™ Analyser
- U.S. Air Force Diabetes Prevention Program

Learn more about our past performance.

Lighting the Path to Discovery

LOCAL LEADERSHIP

EGS ATLANTA OFFICE
2835 Brandywine Rd.
Suite 200
Atlanta, GA 30341

VP FOR LIFE SCIENCES
James M. Watt, PhD
Atlanta,GA
205.213.0967
james.watt@eglobal.science